Make prevention a priority by vaccinating against meningococcal disease

Get to know the most common serogroups in the US


Currently, there are 5 vaccine-preventable serogroups of meningococcal disease in the United States: A, C, W, Y, and B.1 In the US, most cases of meningococcal disease have been caused by serogroups B, C, and Y.1


Prevalence of Meningococcal Disease by Serogroup in the US2,*



*In patients aged <1 to ≥65 years, from 2009-2018.

Includes W and serogroups unable to be identified.

Help protect appropriate patients with 2 different types of vaccines


Your appropriate patients need 2 different types of vaccines to help protect them from meningococcal disease—one for serogroups A, C, W, and Y, and one for serogroup B.3


To learn more about the different types of vaccines, click on the following:



Are you up-to-date on the CDC MenB vaccination recommendation?


Looking for more education? Register for upcoming webinars.



Vaccination may not protect all recipients.



CDC=Centers for Disease Control and Prevention; MenB=meningococcal serogroup B disease; MenACWY=meningococcal serogroups A, C, W, and Y disease.


References: 1. Centers for Disease Control and Prevention. Meningococcal disease: causes and spread to others. Updated May 31, 2019. Accessed January 16, 2020. 2. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). Neisseria meningitidis, 2009-2018. Updated April 5, 2019. Accessed January 13, 2020. 3. Centers for Disease Control and Prevention. Meningococcal vaccination for adolescents: Information for healthcare professionals. Updated July 26, 2019. Accessed January 16, 2020.  


Trademarks are owned by or licensed to the GSK group of companies.


This website is funded and developed by GSK.

This site is intended for US healthcare professionals only.

The GSK Response Center is available to answer your questions at 1-888-593-5977, Monday-Friday, 8:30 am - 5:30 pm ET.

During the hours the GSK Response Center is not available, please feel free to Contact GSK.